How to prevent and manage hyperammonemic encephalopathies in valproate therapy
Mitschek M, Vanicek T, Unterholzner J, Kraus C, Weidenauer A, Naderi-Heiden A, Frey R, Silberbauer L, Gryglewski G, Papageorgiou K, Winkler D, Dold M, Kasper S, Praschak-Rieder N, Bartova L. How to prevent and manage hyperammonemic encephalopathies in valproate therapy. Journal Of Affective Disorders Reports 2021, 5: 100186. DOI: 10.1016/j.jadr.2021.100186.Peer-Reviewed Case Reports and Technical NotesSevere cognitive impairmentValproic acidHyperammonemic encephalopathyPlasma levelsCognitive impairmentPotential drug interactionsYoung male patientLife-threatening symptomsUrea cycle deficiencyUrea cycle defectsValproate therapyMale patientsCase seriesFemale patientsUrinary levelsComatose stateDrug interactionsIndividual patientsPsychotic episodePatientsAffective symptomsCurrent psychotic episodePsychiatric inpatientsPolypharmacyEncephalopathy